Key indicators: single-crystal X-ray study; T = 150 K; mean (C-C) = 0.003 Å; R factor = 0.044; wR factor = 0.127; data-to-parameter ratio = 15.9.
In the title compound (systematic name: {(3aS,5S,6R,6aS)-3a-[(benzyloxy)methyl]-6-hydroxy-2,2-dimethyltetrahydrofuro-[2,3-d][1,3]dioxol-5-yl}methyl 4-methylbenzenesulfonate), C 23 H 28 O 8 S, the absolute structure and relative stereochemistry of the four chiral centres have been established by X-ray crystallography, with the absolute configuration inferred from the use of l-sorbose as the starting material. The central furanose ring adopts a slightly twisted envelope conformation (with the C atom bearing the methylbenzenesulfonate substituent as the flap) from which three substituents depart pseudo-axially (-CH 2 -O-benzyl, -OH and one acetonide O atom) and two substituents pseudo-equatorially (-CH 2 -Otosyl and second acetonide O atom). The dioxalane ring is in a flattened envelope conformation with the fused CH C atom as the flap. In the crystal, molecules pack in columns along [010] linked by O-HÁ Á ÁO hydrogen bonds involving the furanose hydroxy group and furanose ether O atom.
Related literature
The title compound is a novel intermediate in the synthesis of 1-deoxynojirimycin (DNJ) analogues. For examples of the use of monosaccharide starting materials in iminosugar syntheses, see: Compain & Martin (2001) ; Cipolla et al. (2003) ; Best, Wang et al. (2010) ; Wilkinson et al. (2010) ; Nash et al. (2011) ; Zhang et al. (2011); Lenagh-Snow et al. (2011) ; Simone et al. (2012) ; Soengas et al. (2012) ; Kato et al. (2012) . For examples of the synthesis of other biologically active compounds from monosaccharides, see: Compain et al. (2009) ; Sridhar et al. (2012) ; Das et al. (2012) ; Dhavale & Matin (2005) ; Compain & Martin (2001) ; Derosa & Maffioli (2012) ; Lew et al. (2000) ; Itzstein et al. (1993) . For glycosidase inhibitors, see: Houston & Blanchfield (2003) . For iminosugars as glycosidase inhibitors, see: Zechel et al. (2003) ; de Melo et al. (2006) ; Compain & Martin (2007) . For examples of the clinical uses of iminosugars, see: Cox et al. (2003) ; Venier et al. (2012) ; Derosa & Maffioli (2012) . For iminosugars in the treatment of cancer, cystic fibrosis and viral diseases, see: Nishimura (2003) ; Lawton & Witty (2011); Best, Jenkinson et al. (2010) ; Compain & Martin (2007) ; Pollock et al. (2008) . For the syntheses of DNJ and its analogues from l-sorbose, see: Beaupere et al. (1989) ; Masson et al. (2000) ; Tamayo et al. (2010); O'Brien & Murphy (2011) . For the synthesis of 1-O-benzoyl-2,3-O-isopropylidene-6-O-tosyl--l-sorbofuranose, which bears structural similarity to the title compound, see: Fehé r & Vargha (1966 Data collection: CrysAlis PRO (Agilent, 2011); cell refinement: CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to solve structure: SIR97 (Altomare et al., 1999); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: Xtal3.6 (Hall et al., 1999) , ORTEPII (Johnson, 1976) 
Comment
Monosaccharides provide a vast and formidable chiral pool of starting materials, whose utilization continues to expand in the enantiospecific syntheses of natural products (Sridhar et al., 2012; Das et al., 2012) , in particular of carbohydrate mimetics of the carbasugar (Derosa & Maffioli, 2012; Lew et al. 2000) , C-glycoside (Compain & Martin, 2001; Dhavale & Matin, 2005; Compain et al., 2009) , THP (Itzstein et al. 1993 ) and iminosugar (Cipolla et al., 2003; Wilkinson et al. (2010); Nash et al., 2011; Zhang et al., 2011; Lenagh-Snow et al., 2011; Simone et al., 2012; Soengas et al. 2012; Best, Wang et al. 2010; Kato et al., 2012) types, to mention a few.
Iminosugars have been recognized as a class of potent inhibitors of glycosidase enzymes (Houston & Blanchfield 2003; Zechel et al., 2003; de Melo et al., 2006; Compain and Martin, 2007) . These potent biological activities have culminated in the marketing of N-butyl-DNJ for the treatment of Gauchers disease (Miglustat) (Cox et al., 2003; Venier et al., 2012) , N-hydroxyethyl-DNJ for type II diabetes (Miglitol) (Derosa & Maffioli, 2012) while other iminosugars have opened up new in-roads in the treatment of cancer (Nishimura, 2003; Lawton & Witty 2011) , cystic fibrosis (Best, Jenkinson et al., 2010) and as antivirals (Compain & Martin, 2007; Pollock et al. 2008 ).
The first synthesis of DNJ (3 in Fig. 1 ) from starting material L-sorbose (1) utilized triphenylphosphine, carbon tetrabromide and lithium azide to effect the key transformation which installs an azido group in place of the C5 hydroxy (Beaupere et al., 1989) . Syntheses of further DNJ derivatives from L-sorbose have been reported (Masson et al., 2000; Tamayo et al., 2010; O′Brien & Murphy, 2011) . The title compound (2 in Fig. 1 ) bears orthogonal protecting groups on four of the five hydroxy groups, thus opening up points of synthetic divergence to novel classes of iminosugar glycomimetics based on a DNJ scaffold.
In the title compound ( Fig. 2 hydrochloric acid solution (1 M, 100 ml) and the organic layers collected, dried over magnesium sulfate, filtered and concentrated in vacuo. The compound crystallized on standing as a pale yellow solid in quantitative yield (4.57 g).
Refinement
All H atoms attached to C atoms were positioned geometrically, and allowed to ride on their parent atoms, with C-H bond lengths of 0.95 Å (Ar-H), 1.0 (CH), 0.99 Å (CH2) or 0.98 Å (CH3), and isotropic displacement parameters set to 1.2 (CH and CH2) or 1.5 times (CH3) the U eq of the parent atom. The H atom attached to O3 was positioned geometrically and allowed to ride on the parent atom, with an O-H bond length of 0.84 Å and isotropic displacement parameters set to 1.5U eq (O).
Computing details
Data collection: CrysAlis PRO (Agilent, 2011); cell refinement: CrysAlis PRO (Agilent, 2011); data reduction: CrysAlis PRO (Agilent, 2011); program(s) used to solve structure: SIR97 (Altomare et al., 1999); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: Xtal3.6 (Hall et al., 1999) , ORTEPII (Johnson, 1976) , et al., 2011) , Mercury (Macrae et al., 2006) and WinGX (Farrugia, 2012) ; software used to prepare material for publication: publCIF (Westrip, (2010) .
Figure 1
Relationship of L-sorbose (1) starting material to title compound (2) and deoxynojirimycin (DNJ) (3)
Figure 2
The molecular structure of the title compound, with anisotropic displacement ellipsoids shown at the 50% probability level.
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Figure 3
Molecular packing diagram (Macrae et al., 2006) with respect to the unit cell. The molecules stack in columns parallel to the b axis, with molecules within a column linked by intermolecular hydrogen bonds (dashed lines) between the hydroxy O3 moiety and the furanose oxygen O4. 3aS,5S,6R,6aS)-3a-[(Benzyloxy)methyl]-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3] Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
{(

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq S1 0.404262 ( 0.0404 (7) 0.0297 (8) 0.0412 (7) 0.0075 (6) 0.0190 (6) 0.0082 (6) O1′ 0.0522 (9) 0.0409 (10) 0.0313 (7) 0.0102 (7) −0.0020 (6) −0.0056 (7) O2 0.0278 (6) 0.0284 (8) 0.0400 (7) 0.0039 (5) 0.0129 (5) 0.0037 (6) O3 0.0356 (7) 0.0208 (7) 0.0417 (7) −0.0025 (5) 0.0161 (6) −0.0016 (5) O4 0.0374 (7) 0.0213 (7) 0.0243 (6) (8) 0.0038 (7) 0.0075 (7) −0.0011 (7) C1′ 0.0326 (9) 0.0459 (13) 0.0328 (9) 0.0097 (9) 0.0017 (8) −0.0080 (9) C2 0.0265 (7) 0.0232 (9) 0.0287 (8) 0.0022 (7) 0.0083 (6) −0.0027 (7) C3 0.0288 (8) 0.0225 (10) 0.0305 (8) 0.0028 (7) 0.0090 (6) 0.0013 (7) C4 0.0292 (8) 0.0217 (9) 0.0249 (8) 0.0005 (7) 0.0059 (6) −0.0003 (7) C5 0.0380 (9) 0.0256 (10) 0.0291 (8) −0.0023 (7) 0.0125 (7) −0.0020 (7) (7) 0.0014 (7) 0.0105 (6) −0.0002 (7) C17 0.0405 (10) 0.0279 (11) 0.0305 (8) −0.0002 (8) 0.0122 (7) 0.0037 (8) C18 0.0419 (10) 0.0355 (12) 0.0287 (9) 0.0067 (9) 0.0081 (7) 0.0033 (8) C19 0.0347 (9) 0.0385 (12) 0.0273 (8) 0.0014 (8) 0.0113 (7) −0.0059 (8) C20
0.0391 (10) 0.0307 (11) 0.0319 (9) −0.0055 (8) 0.0127 (7) −0.0024 (8) C21 0.0385 (9) 0.0284 (11) 0.0264 (8) −0.0018 (8) 0.0104 (7) 0.0022 (7) C22 0.0367 (10) 0.0585 (16) 0.0400 (11) −0.0008 (10) 0.0069 (8) −0.0096 (11)
Geometric parameters (Å, º) S1-O6 1.4278 (17) C8-C9 1.384 (4) S1-O7 1.4326 (16) C8-H8 0.9500 S1-O5 1.5736 (13) C9-C10 1.382 (6) S1-C16 
